Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06683092 · ClinicalTrials.gov registry record
Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)
A clinical trial of Cystic Fibrosis, sponsored by Boston Children's Hospital.
- Recruiting
- Registry status
- 200
- Enrollment target
- 18
- Study locations
NCT06683092 is a study of Cystic Fibrosis that is actively recruiting participants, run by Boston Children's Hospital. The registered enrollment target is 200 participants, above the 178-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (12% higher). The trial reports 18 study locations across 14 states.
The verdict
NCT06683092, a study of Cystic Fibrosis, is actively recruiting participants, sponsored by Boston Children's Hospital.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 18
- Study locations
Study Summary
RETRIAL is a multi-site observational study of people with Cystic Fibrosis (PWCF) ages 6 and up starting the new triple-therapy modulator (vanzacaftor/tezacaftor/deutivacaftor (VTD)), after having experienced neuropsychiatric events and/or liver injury while taking elexacaftor/tezacaftor/ivacaftor (ETI) that resulted in a modification or discontinuation of standard ETI dosing.
Conditions Studied
Interventions
- OTHER RETRIAL-Mental Health
- OTHER RETRIAL-Liver
- OTHER RETRIAL-Neuro
Study Locations (18)
Florida
- Nemours Children's - Jacksonville
- Nemours Children's - Orlando
- Nemours Children's - Pensacola
Colorado
- Children's Hospital Colorado - Aurora
- National Jewish Health - Denver
Massachusetts
- Massachusetts General Hospital - Boston
- Boston Children's Hospital - Boston
Alabama
- University of Alabama at Birmingham - Birmingham
Delaware
- Nemours Children's - Wilmington
Georgia
- Emory University - Atlanta
Indiana
- Indiana University - Bloomington
Kansas
- Kansas University Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-05-01 |
| Est. Completion | 2028-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06683092
The ClinicalTrials.gov registry entry for NCT06683092 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 178-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (12% higher). The listed sponsor is Boston Children's Hospital, which has 462 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 3 interventions - of which RETRIAL-Mental Health is the first listed.
NCT06683092 reports 18 study locations spanning 14 distinct geographic areas - top geographies include Florida, Colorado, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06683092 about?
NCT06683092 is a clinical study titled "Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)". RETRIAL is a multi-site observational study of people with Cystic Fibrosis (PWCF) ages 6 and up starting the new triple-therapy modulator (vanzacaftor/tezacaftor/deutivacaftor (VTD)), after having experienced neuropsychiatric events and/or liver injury while taking elexacaftor/tezacaftor/ivacaftor (...
What is the current status of trial NCT06683092?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2025-05-01. Estimated completion is 2028-06.
What conditions does trial NCT06683092 study?
This clinical trial studies the following conditions: Cystic Fibrosis.
What interventions are being tested in trial NCT06683092?
The interventions under investigation include: RETRIAL-Mental Health (OTHER), RETRIAL-Liver (OTHER), RETRIAL-Neuro (OTHER).
Who is sponsoring clinical trial NCT06683092?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06683092 being conducted?
This trial has 18 study locations across Alabama, Colorado, Delaware, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Exercise in Child Health
RECRUITING · NA
-
Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.
RECRUITING · Phase 2
-
A Pilot and Feasibility Study to Evaluate High vs Low Glycemic Index Mixed Meal Tolerance Test in Adolescents and Young Adults With Cystic Fibrosis
RECRUITING · NA
-
A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
RECRUITING
-
Assessing Tenapanor as a Treatment of CF-related Constipation.
RECRUITING · Phase 3
-
Genetics of Insulin and Incretins in Cystic Fibrosis
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.